# The Efficacy and Safety of a Selective Estrogen Receptor Beta Agonist (LY500307) for Negative Symptoms and Cognitive Impairment Associated With Schizophrenia

> **NCT01874756** · PHASE2 · TERMINATED · sponsor: **Indiana University** · enrollment: 95 (actual)

## Conditions studied

- Schizophrenia

## Interventions

- **DRUG:** LY500307 150mg
- **DRUG:** LY500307 75mg
- **DRUG:** Placebo
- **DRUG:** LY500307 25mg

## Key facts

- **NCT ID:** NCT01874756
- **Lead sponsor:** Indiana University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2013-06
- **Primary completion:** 2017-12
- **Final completion:** 2017-12
- **Target enrollment:** 95 (ACTUAL)
- **Why stopped:** Funding ended
- **Last updated:** 2019-07-02

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01874756

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01874756, "The Efficacy and Safety of a Selective Estrogen Receptor Beta Agonist (LY500307) for Negative Symptoms and Cognitive Impairment Associated With Schizophrenia". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT01874756. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*